(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

• ChemBase ID: 73222
• Molecular Formular: C10H17N3S
• Molecular Mass: 211.32708
• Monoisotopic Mass: 211.11431856
• SMILES: [C@@H]1(CCc2c(C1)sc(n2)N)NCCC
• Canonical SMILES: CCCN[C@H]1CCc2c(C1)sc(n2)N
• InChI: InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
• InChIKey: FASDKYOPVNHBLU-ZETCQYMHSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
• IUPAC Traditional name: pramipexole
• Synonyms: Mirapexin; Sifrol; Pramipexole (Mirapex); (S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine Dihydrochloride; (S)-Pramipexole Dihydrochloride; (S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine; (S)-Pramipexole

Database IDs

• CAS Number: 104632-25-9; 104632-26-0
• PubChem SID: 162038142
• PubChem CID: 119570

CALCULATED PROPERTIES

• Acid pKa: 17.661047
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): -1.5217185
• LogD (pH = 7.4): -0.98125774
• Log P: 1.7642827
• Molar Refractivity: 59.7672 cm^3
• Polarizability: 22.761166 Å^3
• Polar Surface Area: 50.94 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: Methanol
• Apperance: Off-White Solid; White Solid
• Melting Point: 127-128°C; 288-290°C

Safety Information

• Storage Condition: -20°C; -20°C Freezer

Pharmacology Properties

• Target: Dopamine receptor

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S2460

Biological Activity:
Pramipexole (Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. Pramipexole (Mirapex) also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. Pramipexole (Mirapex) has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. Pramipexole (Mirapex) is a non-ergoline dopamine agonist revealed for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS). [1][2][3]References on Pramipexole (Mirapex)[1] http://en.wikipedia.org/wiki/Pramipexole, , [2] Clin Ther., 2006 Aug, 28(8):1065-78.[3] J Pharmacol Exp Ther., 2002 Nov, 303(2):805-14.

Toronto Research Chemicals - P700755

A dopamine-D2-receptor agonist. Antiparkinsonian.

Toronto Research Chemicals - P700750

(S)-Pramipexole enantiomer. A dopamine-D2-receptor agonist. Antiparkinsonian. Pramipexole (Mirapex, Mirapexin, Sifrol) is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) and restless legs syndrome (RLS).[1] It i

REFERENCES

• Kvernmo T et al. Clin Ther. 2006 Aug;28(8):1065-78.
• Schilling, J.C., et al.: Clin. Pharmacol. Ther., 51, 541 (1992)
• Kieburtz, K., et al.: J. Am. Med. Assoc., 278, 125 (1997)
• Mierau, J., et al.: J. Med. Chem., 30, 494 (1987)
• Schilling, J.C., et al.: Clin. Pharmacol. Ther., 51, 541 (1987)
• Kieburtz, K., et al.: J. Am. Med. Assoc., 278, 125 (1997)